Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisano CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C.

J Pharmacol Exp Ther. 2018 Oct 5. pii: jpet.118.251645. doi: 10.1124/jpet.118.251645. [Epub ahead of print]

2.

NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.

Mellone M, Zianni E, Stanic J, Campanelli F, Marino G, Ghiglieri V, Longhi A, Thiolat ML, Li Q, Calabresi P, Bezard E, Picconi B, Di Luca M, Gardoni F.

Neurobiol Dis. 2018 Sep 24. pii: S0969-9961(18)30300-0. doi: 10.1016/j.nbd.2018.09.021. [Epub ahead of print]

PMID:
30261285
3.

Lack of the Actin Capping Protein, Eps8, Affects NMDA-Type Glutamate Receptor Function and Composition.

Morini R, Ferrara S, Perrucci F, Zambetti S, Pelucchi S, Marcello E, Gardoni F, Antonucci F, Matteoli M, Menna E.

Front Mol Neurosci. 2018 Sep 5;11:313. doi: 10.3389/fnmol.2018.00313. eCollection 2018.

4.

Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum.

Maltese M, Stanic J, Tassone A, Sciamanna G, Ponterio G, Vanni V, Martella G, Imbriani P, Bonsi P, Mercuri NB, Gardoni F, Pisani A.

Elife. 2018 Mar 5;7. pii: e33331. doi: 10.7554/eLife.33331.

5.

Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.

Mellone M, Gardoni F.

J Neural Transm (Vienna). 2018 Aug;125(8):1225-1236. doi: 10.1007/s00702-018-1846-8. Epub 2018 Jan 31.

PMID:
29387966
6.

Synapse-to-nucleus communication: from developmental disorders to Alzheimer's disease.

Marcello E, Di Luca M, Gardoni F.

Curr Opin Neurobiol. 2018 Feb;48:160-166. doi: 10.1016/j.conb.2017.12.017. Epub 2018 Jan 6. Review.

PMID:
29316492
7.

Publisher Correction: Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target.

Borroni B, Stanic J, Verpelli C, Mellone M, Bonomi E, Alberici A, Bernasconi P, Culotta L, Zianni E, Archetti S, Manes M, Gazzina S, Ghidoni R, Benussi L, Stuani C, Di Luca M, Sala C, Buratti E, Padovani A, Gardoni F.

Sci Rep. 2018 Jan 5;8(1):272. doi: 10.1038/s41598-017-18750-8.

8.

Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin.

Borroni B, Benussi A, Premi E, Alberici A, Marcello E, Gardoni F, Di Luca M, Padovani A.

J Alzheimers Dis. 2018;62(3):1113-1123. doi: 10.3233/JAD-170584.

9.

ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimer's disease.

Marcello E, Borroni B, Pelucchi S, Gardoni F, Di Luca M.

Expert Opin Ther Targets. 2017 Nov;21(11):1017-1026. doi: 10.1080/14728222.2017.1386176. Epub 2017 Oct 3. Review.

PMID:
28960088
10.

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.

Stanic J, Mellone M, Napolitano F, Racca C, Zianni E, Minocci D, Ghiglieri V, Thiolat ML, Li Q, Longhi A, De Rosa A, Picconi B, Bezard E, Calabresi P, Di Luca M, Usiello A, Gardoni F.

Neurobiol Dis. 2017 Dec;108:54-64. doi: 10.1016/j.nbd.2017.08.001. Epub 2017 Aug 18.

11.

Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target.

Borroni B, Stanic J, Verpelli C, Mellone M, Bonomi E, Alberici A, Bernasconi P, Culotta L, Zianni E, Archetti S, Manes M, Gazzina S, Ghidoni R, Benussi L, Stuani C, Di Luca M, Sala C, Buratti E, Padovani A, Gardoni F.

Sci Rep. 2017 Jul 27;7(1):6723. doi: 10.1038/s41598-017-06117-y. Erratum in: Sci Rep. 2018 Jan 5;8(1):272.

12.

Fingolimod Limits Acute Aβ Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons.

Joshi P, Gabrielli M, Ponzoni L, Pelucchi S, Stravalaci M, Beeg M, Mazzitelli S, Braida D, Sala M, Boda E, Buffo A, Gobbi M, Gardoni F, Matteoli M, Marcello E, Verderio C.

Sci Rep. 2017 Jan 30;7:41734. doi: 10.1038/srep41734.

13.

Coxsackievirus Adenovirus Receptor Loss Impairs Adult Neurogenesis, Synapse Content, and Hippocampus Plasticity.

Zussy C, Loustalot F, Junyent F, Gardoni F, Bories C, Valero J, Desarménien MG, Bernex F, Henaff D, Bayo-Puxan N, Chen JW, Lonjon N, de Koninck Y, Malva JO, Bergelson JM, di Luca M, Schiavo G, Salinas S, Kremer EJ.

J Neurosci. 2016 Sep 14;36(37):9558-71. doi: 10.1523/JNEUROSCI.0132-16.2016.

14.

LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.

Stanic J, Mellone M, Cirnaru MD, Perez-Carrion M, Zianni E, Di Luca M, Gardoni F, Piccoli G.

Mol Brain. 2016 May 11;9(1):53. doi: 10.1186/s13041-016-0234-2.

15.

Ring finger protein 10 is a novel synaptonuclear messenger encoding activation of NMDA receptors in hippocampus.

Dinamarca MC, Guzzetti F, Karpova A, Lim D, Mitro N, Musardo S, Mellone M, Marcello E, Stanic J, Samaddar T, Burguière A, Caldarelli A, Genazzani AA, Perroy J, Fagni L, Canonico PL, Kreutz MR, Gardoni F, Di Luca M.

Elife. 2016 Mar 15;5:e12430. doi: 10.7554/eLife.12430.

16.

Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex.

Stanic J, Carta M, Eberini I, Pelucchi S, Marcello E, Genazzani AA, Racca C, Mulle C, Di Luca M, Gardoni F.

Nat Commun. 2015 Dec 18;6:10181. doi: 10.1038/ncomms10181.

17.

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, Napolitano F, di Maio A, Mellone M, Stanic J, Tronci E, Fidalgo C, Stancampiano R, Carta M, Calabresi P, Gardoni F, Usiello A, Picconi B.

Neurobiol Dis. 2016 Feb;86:140-53. doi: 10.1016/j.nbd.2015.11.022. Epub 2015 Nov 27.

PMID:
26639853
18.

Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit.

Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di Filippo M, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampà C, Dalley JW, Xia J, Gardoni F, Mellone M, El-Agnaf OM, Ardah MT, Puglisi-Allegra S, Björklund A, Spillantini MG, Picconi B, Calabresi P.

Biol Psychiatry. 2016 Mar 1;79(5):402-414. doi: 10.1016/j.biopsych.2015.08.013. Epub 2015 Aug 20.

PMID:
26392130
19.

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.

Mellone M, Stanic J, Hernandez LF, Iglesias E, Zianni E, Longhi A, Prigent A, Picconi B, Calabresi P, Hirsch EC, Obeso JA, Di Luca M, Gardoni F.

Front Cell Neurosci. 2015 Jul 6;9:245. doi: 10.3389/fncel.2015.00245. eCollection 2015.

20.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E.

Prog Neurobiol. 2015 Sep;132:96-168. doi: 10.1016/j.pneurobio.2015.07.002. Epub 2015 Jul 21. Review.

PMID:
26209473
21.

Alzheimer's disease and modern lifestyle: what is the role of stress?

Marcello E, Gardoni F, Di Luca M.

J Neurochem. 2015 Sep;134(5):795-8. doi: 10.1111/jnc.13210. Epub 2015 Jul 23.

22.

Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome.

Pasciuto E, Ahmed T, Wahle T, Gardoni F, D'Andrea L, Pacini L, Jacquemont S, Tassone F, Balschun D, Dotti CG, Callaerts-Vegh Z, D'Hooge R, Müller UC, Di Luca M, De Strooper B, Bagni C.

Neuron. 2015 Jul 15;87(2):382-98. doi: 10.1016/j.neuron.2015.06.032. Erratum in: Neuron. 2015 Aug 19;87(4):908.

23.

Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors.

Di Filippo M, Tozzi A, Arcangeli S, de Iure A, Durante V, Di Gregorio M, Gardoni F, Calabresi P.

Neuropharmacology. 2016 Jan;100:98-105. doi: 10.1016/j.neuropharm.2015.06.009. Epub 2015 Jun 24.

PMID:
26116817
24.

Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases.

Gardoni F, Bellone C.

Front Cell Neurosci. 2015 Mar 2;9:25. doi: 10.3389/fncel.2015.00025. eCollection 2015. Review.

25.

d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain.

Cristino L, Luongo L, Squillace M, Paolone G, Mango D, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, Nisticò R, Usiello A.

Neurobiol Aging. 2015 May;36(5):1890-902. doi: 10.1016/j.neurobiolaging.2015.02.003. Epub 2015 Feb 12.

PMID:
25771393
26.

Cocaine-evoked negative symptoms require AMPA receptor trafficking in the lateral habenula.

Meye FJ, Valentinova K, Lecca S, Marion-Poll L, Maroteaux MJ, Musardo S, Moutkine I, Gardoni F, Huganir RL, Georges F, Mameli M.

Nat Neurosci. 2015 Mar;18(3):376-8. doi: 10.1038/nn.3923. Epub 2015 Feb 2.

27.

Targeting glutamatergic synapses in Parkinson's disease.

Gardoni F, Di Luca M.

Curr Opin Pharmacol. 2015 Feb;20:24-8. doi: 10.1016/j.coph.2014.10.011. Epub 2014 Nov 17. Review.

PMID:
25462288
28.

SAP97-mediated ADAM10 trafficking from Golgi outposts depends on PKC phosphorylation.

Saraceno C, Marcello E, Di Marino D, Borroni B, Claeysen S, Perroy J, Padovani A, Tramontano A, Gardoni F, Di Luca M.

Cell Death Dis. 2014 Nov 27;5:e1547. doi: 10.1038/cddis.2014.492.

29.

Zinc transporter-1: a novel NMDA receptor-binding protein at the postsynaptic density.

Mellone M, Pelucchi S, Alberti L, Genazzani AA, Di Luca M, Gardoni F.

J Neurochem. 2015 Jan;132(2):159-68. doi: 10.1111/jnc.12968. Epub 2015 Jan 4.

30.

The role of the conformational profile of polysaccharides on skin penetration: the case of hyaluronan and its sulfates.

Cilurzo F, Vistoli G, Gennari CG, Selmin F, Gardoni F, Franzè S, Campisi M, Minghetti P.

Chem Biodivers. 2014 Apr;11(4):551-61. doi: 10.1002/cbdv.201300130.

PMID:
24706625
31.

Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neurons.

Heise C, Gardoni F, Culotta L, di Luca M, Verpelli C, Sala C.

Front Cell Neurosci. 2014 Feb 10;8:35. doi: 10.3389/fncel.2014.00035. eCollection 2014. Review.

32.

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, Gardoni F, Carta M.

Neuroscience. 2014 Apr 18;265:245-52. doi: 10.1016/j.neuroscience.2014.01.042. Epub 2014 Jan 30.

PMID:
24486947
33.

Diabetic neuropathic pain: a role for testosterone metabolites.

Calabrese D, Giatti S, Romano S, Porretta-Serapiglia C, Bianchi R, Milanese M, Bonanno G, Caruso D, Viviani B, Gardoni F, Garcia-Segura LM, Melcangi RC.

J Endocrinol. 2014 Mar 7;221(1):1-13. doi: 10.1530/JOE-13-0541. Print 2014 Apr.

PMID:
24424289
34.

Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism.

Rylander D, Bagetta V, Pendolino V, Zianni E, Grealish S, Gardoni F, Di Luca M, Calabresi P, Cenci MA, Picconi B.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):E4375-84. doi: 10.1073/pnas.1311187110. Epub 2013 Oct 29.

35.

Early maternal deprivation immunologically primes hippocampal synapses by redistributing interleukin-1 receptor type I in a sex dependent manner.

Viviani B, Boraso M, Valero M, Gardoni F, Marco EM, Llorente R, Corsini E, Galli CL, Di Luca M, Marinovich M, López-Gallardo M, Viveros MP.

Brain Behav Immun. 2014 Jan;35:135-43. doi: 10.1016/j.bbi.2013.09.008. Epub 2013 Sep 21.

36.

ADAM10 in synaptic physiology and pathology.

Musardo S, Marcello E, Gardoni F, Di Luca M.

Neurodegener Dis. 2014;13(2-3):72-4. doi: 10.1159/000354233. Epub 2013 Sep 4. Review.

PMID:
24008925
37.

Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system.

Mellone M, Gardoni F.

Eur J Pharmacol. 2013 Nov 5;719(1-3):75-83. doi: 10.1016/j.ejphar.2013.04.054. Epub 2013 Jul 18. Review.

PMID:
23872417
38.

SNAP-25 regulates spine formation through postsynaptic binding to p140Cap.

Tomasoni R, Repetto D, Morini R, Elia C, Gardoni F, Di Luca M, Turco E, Defilippi P, Matteoli M.

Nat Commun. 2013;4:2136. doi: 10.1038/ncomms3136.

39.

Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease.

Marcello E, Saraceno C, Musardo S, Vara H, de la Fuente AG, Pelucchi S, Di Marino D, Borroni B, Tramontano A, Pérez-Otaño I, Padovani A, Giustetto M, Gardoni F, Di Luca M.

J Clin Invest. 2013 Jun;123(6):2523-38. doi: 10.1172/JCI65401. Epub 2013 May 8.

40.

Effects of central and peripheral inflammation on hippocampal synaptic plasticity.

Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampà C, Costa C, Tantucci M, Zianni E, Boraso M, Siliquini S, de Iure A, Ghiglieri V, Colcelli E, Baker D, Sarchielli P, Fusco FR, Di Luca M, Calabresi P.

Neurobiol Dis. 2013 Apr;52:229-36. doi: 10.1016/j.nbd.2012.12.009. Epub 2013 Jan 4.

PMID:
23295855
41.

Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Bagetta V, Sgobio C, Pendolino V, Del Papa G, Tozzi A, Ghiglieri V, Giampà C, Zianni E, Gardoni F, Calabresi P, Picconi B.

J Neurosci. 2012 Dec 5;32(49):17921-31. doi: 10.1523/JNEUROSCI.2664-12.2012.

42.

Aβ leads to Ca²⁺ signaling alterations and transcriptional changes in glial cells.

Grolla AA, Fakhfouri G, Balzaretti G, Marcello E, Gardoni F, Canonico PL, DiLuca M, Genazzani AA, Lim D.

Neurobiol Aging. 2013 Feb;34(2):511-22. doi: 10.1016/j.neurobiolaging.2012.05.005. Epub 2012 Jun 5.

PMID:
22673114
43.

Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.

Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, Latagliata EC, Pascucci T, Puglisi-Allegra S, Gardoni F, Di Luca M, Picconi B, Calabresi P.

Brain. 2012 Jun;135(Pt 6):1884-99. doi: 10.1093/brain/aws101. Epub 2012 May 4.

PMID:
22561640
44.

N-methyl-D-aspartate (NMDA) receptor composition modulates dendritic spine morphology in striatal medium spiny neurons.

Vastagh C, Gardoni F, Bagetta V, Stanic J, Zianni E, Giampà C, Picconi B, Calabresi P, Di Luca M.

J Biol Chem. 2012 May 25;287(22):18103-14. doi: 10.1074/jbc.M112.347427. Epub 2012 Apr 9.

45.

The neuropeptide PACAP38 induces dendritic spine remodeling through ADAM10-N-cadherin signaling pathway.

Gardoni F, Saraceno C, Malinverno M, Marcello E, Verpelli C, Sala C, Di Luca M.

J Cell Sci. 2012 Mar 15;125(Pt 6):1401-6. doi: 10.1242/jcs.097576. Epub 2012 Feb 10.

46.

Increased [³H]D-aspartate release and changes in glutamate receptor expression in the hippocampus of the mnd mouse.

Bigini P, Milanese M, Gardoni F, Longhi A, Bonifacino T, Barbera S, Fumagalli E, Di Luca M, Mennini T, Bonanno G.

J Neurosci Res. 2012 Jun;90(6):1148-58. doi: 10.1002/jnr.22831. Epub 2012 Feb 3.

PMID:
22302580
47.

Alpha, beta-and gamma-secretases in Alzheimer's disease.

Epis R, Marcello E, Gardoni F, Di Luca M.

Front Biosci (Schol Ed). 2012 Jan 1;4:1126-50. Review.

PMID:
22202113
48.

Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.

Errico F, Bonito-Oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, Napolitano F, Marinucci S, Di Luca M, Calabresi P, Fisone G, Carta M, Picconi B, Gardoni F, Usiello A.

Exp Neurol. 2011 Dec;232(2):240-50. doi: 10.1016/j.expneurol.2011.09.013. Epub 2011 Sep 17.

PMID:
21946266
49.

Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.

Gardoni F, Zianni E, Eramo A, Canonico PL, Di Luca M.

Eur J Pharmacol. 2011 Nov 30;670(2-3):458-63. doi: 10.1016/j.ejphar.2011.09.028. Epub 2011 Sep 21.

50.

Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.

Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B.

Neurobiol Aging. 2012 Sep;33(9):2138-44. doi: 10.1016/j.neurobiolaging.2011.06.019. Epub 2011 Aug 6.

PMID:
21821315

Supplemental Content

Loading ...
Support Center